Literature DB >> 8288500

Antimicrobial susceptibility of Rochalimaea quintana, Rochalimaea vinsonii, and the newly recognized Rochalimaea henselae.

M Maurin1, D Raoult.   

Abstract

The susceptibility of an isolate of Rochalimaea quintana, Rochalimaea vinsonii and the newly recognized Rochalimaea henselae to antimicrobial agents was determined by dilution in Mueller-Hinton agar supplemented with 5% sheep blood. Two inocula of 10(2) and 10(4) cfu were used and tests were read after incubation at 5 and 7 days at 37 degrees C in an atmosphere enriched to 5% carbon dioxide. Each isolate was susceptible to amoxycillin, third-generation cephalosporins, tetracyclines, macrolides and rifampicin, with complete inhibition of bacterial growth at concentrations lower than 0.125 mg/L. Co-trimoxazole and aminoglycosides were also active. Conversely, MICs for oxacillin, cephalothin, clindamycin, chloramphenicol and the fluoroquinolones were around the maximum concentrations achievable in serum. Vanocomycin showed moderate activity with MICs of < or = 4 mg/L. These results are consistent with clinical experience in antibiotic treatment of R. henselae infections since failures were reported with first-generation cephalosporins and the isoxazolyl penicillins. However, the frequent relapses that are observed with other beta-lactams, tetracyclines or macrolides do not accord with the in-vitro susceptibility of Rochalimaea spp. Poor bactericidal activity as well as the intracellular growth of the bacteria within infected hosts, may explain such discrepancies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8288500     DOI: 10.1093/jac/32.4.587

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

Review 1.  Natural history of Bartonella infections (an exception to Koch's postulate).

Authors:  V Jacomo; P J Kelly; Didier Raoult
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

Review 2.  Recommendations for treatment of human infections caused by Bartonella species.

Authors:  J M Rolain; P Brouqui; J E Koehler; C Maguina; M J Dolan; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

3.  Multiple recurrent bacillary angiomatosis due to Bartonella quintana in an HIV-infected patient.

Authors:  P Colson; L Lebrun; M Drancourt; F Boué; D Raoult; P Nordmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-02       Impact factor: 3.267

Review 4.  Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.

Authors:  N Principi; S Esposito
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

5.  Genomic variation of Bartonella henselae strains detected in lymph nodes of patients with cat scratch disease.

Authors:  Zaher Zeaiter; Pierre-Edouard Fournier; Didier Raoult
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 6.  Bartonella spp. as emerging human pathogens.

Authors:  B E Anderson; M A Neuman
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

7.  Culture-negative endocarditis: contribution of bartonella infections.

Authors:  A S Breathnach; J M Hoare; S J Eykyn
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

8.  Efficacy of enrofloxacin or doxycycline for treatment of Bartonella henselae or Bartonella clarridgeiae infection in cats.

Authors:  D L Kordick; M G Papich; E B Breitschwerdt
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

9.  Intraerythrocytic presence of Bartonella henselae.

Authors:  D L Kordick; E B Breitschwerdt
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

10.  Endocarditis in a dog due to infection with a novel Bartonella subspecies.

Authors:  E B Breitschwerdt; D L Kordick; D E Malarkey; B Keene; T L Hadfield; K Wilson
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.